Cargando…
Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS
BACKGROUND: The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall ou...
Autores principales: | Häberle, Helene, Magunia, Harry, Lang, Peter, Gloeckner, Henning, Körner, Andreas, Koeppen, Michael, Backchoul, Tamam, Malek, Nisar, Handgretinger, Rupert, Rosenberger, Peter, Mirakaj, Valbona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145440/ https://www.ncbi.nlm.nih.gov/pubmed/33663244 http://dx.doi.org/10.1177/0885066621997365 |
Ejemplares similares
-
Early vvECMO implantation may be associated with lower mortality in ARDS
por: Rosenberger, Peter, et al.
Publicado: (2023) -
Early Driving Pressure Changes Predict Outcomes during Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome
por: Magunia, Harry, et al.
Publicado: (2020) -
COVID-19 does not influence functional status after ARDS therapy
por: Bernard, Alice, et al.
Publicado: (2023) -
Neuronal guidance proteins in cardiovascular inflammation
por: Keller, Marius, et al.
Publicado: (2021) -
Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19
por: Zlamal, Jan, et al.
Publicado: (2022)